(Q40551050)

English

A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma

scientific article published on September 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

author name string

Einsele H

1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Bamberg M

2

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Budach W

3

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Schmidberger H

4

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Hess CF

5

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Wörmann B

6

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Meisner C

7

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Straka C

8

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Hebart H

9

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Trümper L

10

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Kröger N

11

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Zander AR

12

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Hegewisch-Becker S

13

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Hossfeld DK

14

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Schmidt H

15

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Müller P

16

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Schlimok G

17

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Hertenstein B

18

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Peest D

19

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Metzner B

20

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Frickhofen N

21

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Kanz L

22

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Bensinger WI

23

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

language of work or name

0 references

publication date

1 September 2003

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

593-599

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704192

0 references

Diagnosis, prognosis, and standard treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704192

21 January 2018

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704192

21 January 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704192

21 January 2018

Indices of relative weight and obesity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704192

21 January 2018

High-dose melphalan for multiple myeloma: long-term follow-up data

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704192

21 January 2018

Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melph

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704192

21 January 2018

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704192

21 January 2018

Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704192

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose intravenous melphalan for plasma-cell leukaemia and myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704192

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704192

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704192

7 January 2021

based on heuristic

inferred from DOI database lookup

Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704192

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704192

7 January 2021

based on heuristic

inferred from DOI database lookup

Peripheral blood progenitor cell transplantation in multiple myeloma following high-dose melphalan-based therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704192

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiation resistance in a melphalan-resistant subline of a rat mammary carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704192

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1704192

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40551050&oldid=1900270703"